Managing Depressive Symptoms in ADPKD
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT07745920
- Status
- Recruiting
Conditions
- Autosomal Dominant Polycystic Kidney Disease
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 70 Years
- Healthy Volunteers
- Not accepted
Interventions
- Mayo Clinic-Approved Education — BEHAVIORALEducation attention control will be administered by board certified health and wellness coaches via virtual coaching sessions.
- Digital Neuropathy — BEHAVIORALThe web-based system (REJUVENATE) consists of a set of cognitive exercises continuously and automatically adjusted in difficulty based on each user's performance to maintain the balance of challenge and success optimal to promote neuroplastic enhancement of target neural systems.
- Capacity Coaching — BEHAVIORALBoard certified health and wellness coaches will create a plan with subjects to use capacity, defined as patients' abilities and resources, to do self-management work.
Study Details
The purpose of this research is to evaluate the feasibility and effectiveness of Digital Neurotherapy (DNT) or Capacity Coaching (CC) for managing symptoms of depression and self reported pain in Autosomal Dominant Polycystic Kidney Disease (ADPKD) compared to education alone.
Key Dates
- First listed
- Aug 4, 2026
- Start date
- Jun 12, 2026
- Status verified
- Aug 2026
- Primary completion
- Jul 12, 2027
- Completion
- Jul 12, 2027
Study Design
- Enrollment
- 105 participants (estimated)
- Allocation
- RANDOMIZED
- Intervention model
- PARALLEL
- Primary purpose
- TREATMENT
Arms
- Active Comparator: Mayo Clinic-Approved EducationThe control group will receive standard of care, Mayo Clinic approved education for a duration of 60 minutes, every 2 weeks for 6 sessions (12 weeks)
- Experimental: Digital NeuropathyThe Digital Neuropathy group will utilize the web-based system (REJUVENATE) for a duration of 20 minutes, 4 times per week (12 weeks)
- Experimental: Capacity CoachingThe Capacity Coaching group will participate in calls with a board certified health and wellness coach for a duration of 60 minutes, every 2 weeks, for 6 sessions (12 weeks)
Primary Outcome Measure
Actual use of intervention [ Time Frame: 12 weeks ]
Central Contacts
- Ryan Helland, CCRP507-422-3998
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic | Rochester | Minnesota | 55905 | Ryan Helland, CCRP 507-422-3998 |
Find similar trials in Rochester, MN
By research site
Related Studies
- Characterization of the Nrf2 Response in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD)Recruiting · Mayo Clinic · Rochester, Minnesota
- NOX4 and Related Biomarkers in ADPKDRecruiting · Mayo Clinic · Rochester, Minnesota
- ANCHOR Study: A Study to Assess the Safety and Efficacy of ABBV-CLS-628 in Adult Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)PHASE2 · Recruiting · Calico Life Sciences LLC · Birmingham, Alabama
- Safety, Tolerability and Pharmacokinetics of AZD1613 in Adults With Autosomal Dominant Polycystic Kidney DiseasePHASE1 · Recruiting · AstraZeneca · Birmingham, Alabama